Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
University of Southern California
Jonsson Comprehensive Cancer Center
Universidad Nacional Autonoma de Mexico
National Cancer Institute (NCI)